Dr. Reddy’s Laboratories has launched its generic Semaglutide Injection in Canada, becoming one of the first companies to introduce a generic Semaglutide Injection in the Canadian market.
The Hyderabad-based company received approval for the launch from Health Canada on April 28, 2026. Canada is the first G7 country to grant market authorisation for Semaglutide Injection. The launch demonstrates Dr. Reddy’s readiness to ensure patient access following approval.
In Canada, Dr. Reddy’s Semaglutide Injection is indicated for the once‑weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.
“We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development,” Erez Israeli, Chief Executive Officer, Dr. Reddy’s said in a release on Saturday.
“With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients. The Canada launch builds on the momentum of our recent launch in India under the brand name Obeda. As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” Israeli added.
When contacted, a company spokesperson declined to disclose the price of the drug in the Canadian market. However, in a recent press conference on Q4 FY26 numbers, Israeli said it would be “competitive”.